Wed, Jun 19, 2019

18th International Forum on Mood and Anxiety Disorders - IFMAD


Start date: 4 Jul 2019
End date: 6 Jul 2019

IFMAD provides an opportunity to listen to leading experts who will provide up to date news on the most recent developments in Mood and Anxiety disorders.

This year is expected a lively discussion on treatment resistant depression with new findings on rapid response within a day in TRD.

The latest findings on the genetic basis of TRD will open the way to the use of personalized treatment of depression to reduce the chance of resistance developing.

There will be overviews of the contribution of inflammation to mood and anxiety disorders and also the link between nutrition and psychiatry. Updates on new antipsychotics in schizophrenia and on the treatment of negative and depressive symptoms in schizophrenia will be presented. New studies on bipolar disorders have helped clarify the issues of treatment of bipolar depression and the associated cognitive impairment. An update on the risks of valproate will question its widespread use. A major current concern, which will be addressed in the meeting, is the apparent overuse of valproate in women of child bearing age. There will be sessions on anxiety disorders and a focus on long-term treatment and on comorbidity with alcohol dependence.

IFMAD 2019 topics will include:

  • Treatment-resistant depression, 
  • Augmentation strategies in MDD,
  •  Inflammation in mood and anxiety disorders, 
  • Cognition in MDD, 
  • Behavioral addictions, 
  • Anxiety disorders with addiction, 
  • Prevention of suicide, 
  • New data on lithium, 
  • Postpartum depression, 
  • Glutamatergic approaches to mood disorders, 
  • Developments in digital psychiatry and cognitive and functional remediation in bipolar disorder.


Abstract submission deadline: 23 January 2019

 15% discount to the registration according to the geographic aread for every member of EFPA.

In order to benefit from this discount, please contact IFMAD at


View all events